Clinical trials: Neurologic Ambulation Disorder
Stroke, Acute, Stroke, Ischemic
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.
- Conditions
- Stroke, Acute, Stroke, Ischemic, Stroke, Subacute, Stroke Hemorrhagic
- Trial name
- EarlyExo (NCT06107010)
- Testing
- Use of the Atalante exoskeleton
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Wandercraft
Multiple Sclerosis
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the Central Nervous System (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain…
- Trial name
- NCT00053417
- Testing
- 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
- Where
- 25 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Acorda Therapeutics
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder
Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop
The objective of this study is to determine the effectiveness of the NESS L300 (L300) in improving gait parameters, function, and quality of life among stroke subjects (greater than or equal to 3 months post stroke)with drop foot.
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis
- Trial name
- L300 (NCT01138995)
- Testing
- Ness L300, Ankle-foot orthosis
- Where
- 11 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bioness Inc
Cerebral Palsy
PlayGait: A Dynamic Exoskeleton
PlayGait is an investigational dynamic energy storage and return (ESR) lower-limb exoskeleton for young children with cerebral palsy (CP), that stores energy while the child is in the stance phase of walking and returns that…
- Trial name
- NCT05318690
- Testing
- PlayGait, Baseline
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Orthocare Innovations, LLC
Spinal Cord Injuries
Clinical Investigation on Feasibility and Usability of the ABLE Exoskeleton Device for Individuals With Spinal Cord Injury to Perform Skills for Home and Community Environments
The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians.
- Trial name
- NCT05643313
- Testing
- ABLE Exoskeleton
- Where
- 2 sites in Germany, Spain
- Volunteers
- 10 people
- Sponsor
- ABLE Human Motion S.L.
Becker Muscular Dystrophy
Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy
This is a Phase 1, open-label, dose escalation study aimed at evaluating the safety, early efficacy and potential biomarkers of (+)-epicatechin in patients with Becker or Becker-like Muscular Dystrophy (BMD).
- Trial name
- NCT04386304
- Testing
- (+)-Epicatechin
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Epirium Bio Inc.
Sarcopenia, Gait Disorders in Old Age
A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)
The main objective of the study is to evaluate the effect of two daily doses of BIO101 versus placebo on mobility function as measured by gait speed using the 400MW test.
- Conditions
- Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
- Trial name
- SARA-INT (NCT03452488)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium
- Volunteers
- 233 people
- Sponsor
- Biophytis
Multiple Sclerosis
EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis
The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body.
- Trial name
- EXO-MOBILITY (NCT07252895)
- Testing
- EXOPULSE Suit in Active mode
- Where
- 11 sites in France
- Volunteers
- 77 people
- Sponsor
- Otto Bock France SNC
Spinal Cord Injuries
KAFO Orthoses Versus the ABLE Exoskeleton
This randomized crossover study will compare walking with KAFO type orthoses (current standard of care) versus the ABLE Exoskeleton device, during walking in patients with spinal cord injury in a hospital setting.
- Trial name
- NCT04855916
- Testing
- ABLE Exoskeleton, KAFO Orthosis
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- ABLE Human Motion S.L.
Stroke, Stroke, Acute
Evaluation of the Use of the Atalante Exoskeleton in Patients Presenting an Hemiplegia Due to Cerebrovascular Accident
The INSPIRE study is interventional, European, prospective, open, multicentric, each patient being his/her own control. It is conducted to assess the safety and performance of the Atalante exoskeleton system in patients…
- Conditions
- Stroke, Stroke, Acute, Stroke, Subacute, Chronic Stroke
- Trial name
- INSPIRE (NCT04694001)
- Testing
- Use of the Atalante exoskeleton
- Where
- 6 sites in Belgium, France and 1 more
- Volunteers
- 40 people
- Sponsor
- Wandercraft
Stroke, Multiple Sclerosis
Evaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application
The aim of this randomized, cross-over, multi-center, intention-to-treat, open-label study study is to determine the benefits of the NEUROSWING device on gait speed in patients with dorsal and/or plantar flexor deficits, compared…
- Conditions
- Stroke, Multiple Sclerosis, Cerebral Palsy, Neuromuscular Deficits
- Trial name
- NS-BOOSST (NCT07108088)
- Testing
- NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation, Carbon orthosis (control)
- Where
- 2 sites in France
- Volunteers
- 34 people
- Sponsor
- ÖSSUR France
Spinal Cord Injury
Indego® Exoskeleton; Assessing Mobility for Persons With Spinal Cord Injury (SCI).
This study will evaluate the Indego® device for safety and effectiveness at allowing persons with SCI who are non-ambulatory or poorly ambulatory to stand up and walk under a variety of conditions.
- Trial name
- Indego (NCT02202538)
- Testing
- Indego
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Parker Hannifin Corporation
Stroke, Stroke, Acute
Evaluation of the Use of the Atalante System in Patients Presenting a Non-traumatic Hemiplegia in Acute-subacute Phase (15 Days to 6 Months).
The SPIRIT study is interventional, national, prospective, open, multicentric each patient being his/her own control. It is conducted to assess the safety and performance of the Atalante exoskeleton system in patients presenting…
- Conditions
- Stroke, Stroke, Acute, Stroke, Subacute, Robotics
- Trial name
- SPIRIT (NCT04187209)
- Testing
- Use of the Atalante exoskeleton
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Wandercraft
Sarcopenia, Gait Disorders in Old Age
An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over
The SARA-OBS is a single arm phase 2 clinical trial, with no investigational product and no therapeutic intervention that will be conducted in three European countries, (Belgium, France and Italy), and in the US.
- Conditions
- Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
- Trial name
- SARA-OBS (NCT03021798)
- Testing
- No Drug and no aspecific intervention
- Where
- 7 sites in United States, Belgium and 2 more
- Volunteers
- 218 people
- Sponsor
- Biophytis
Spinal Cord Injuries (SCI), Paraplegia and Tetraplegia
Self-balancing Personal Exoskeleton for SCI (Site 2)
This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).
- Trial name
- NCT06814015
- Testing
- Hands-free exoskeleton
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wandercraft
Spinal Cord Injury, Exoskeleton Device
Safety and Efficacy of the UNILEXA Exoskeleton for Regular Verticalization and Assisted Walking
The primary objective of this clinical follow-up is to analyze data regarding the safety of the UNILEXA passive exoskeleton post-market.
- Trial name
- NCT06782113
- Where
- Czechia
- Volunteers
- 6 people
- Sponsor
- MEBSTER
Multiple Sclerosis
Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.
The objectives of this study in Multiple Sclerosis (MS) participants treated with prolonged-released fampridine (BIIB041) 10 mg twice daily compared with participants treated with placebo are to assess the effect over 24 weeks on…
- Trial name
- MOBILE (NCT01597297)
- Testing
- BIIB041 (PR Fampridine)
- Where
- 23 sites in Belgium, Canada and 4 more
- Volunteers
- 132 people
- Sponsor
- Biogen
Spinal Cord Injuries (SCI), Paraplegia and Tetraplegia
Self-balancing Personal Exoskeleton for SCI
This study aims to demonstrate the safety and effectiveness of the Eve personal exoskeleton in individuals with spinal cord injury (SCI).
- Trial name
- NCT06777576
- Testing
- Hands-free exoskeleton
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wandercraft
Cerebral Palsy, Gait Disorders
The Effects of Exoskeletal Robot-Assisted Gait Training on Children With Cerebral Palsy: A Pilot Study
Cerebral Palsy (CP) is a complex neurodevelopmental disorder caused by early brain injury, leading to motor impairments such as muscle weakness, stiffness, and gait instability, which impact daily functioning.
- Conditions
- Cerebral Palsy, Gait Disorders, Gait Disorders in Children, Gait Disorders, Neurologic
- Trial name
- NCT05759182
- Testing
- Powered Exoskeleton Gait Training
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- COSMO ROBOTICS CO., Ltd
Walking Impairment, Multiple Sclerosis
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the…
- Trial name
- NCT02471222
- Testing
- ADS-5102
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adamas Pharmaceuticals, Inc.